Results 271 to 280 of about 1,186,610 (361)

Study on the expression level of folate receptor γ in thyroid cancer and its association with clinicopathological characteristics. [PDF]

Oncol Lett
Cao J, Li Y, Deng X, Lv B, Han L, Tong L.   +5 more
europepmc   +1 more source

Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data

Clinical Pharmacology &Therapeutics, EarlyView.
A considerable number of oral antitumor therapeutics (OAT) has the potential for causing pseudo‐worsening of kidney function (PW) due to inhibition of renal creatinine secretion, i.e., kidney function is unaffected, while creatinine‐based calculation of glomerular filtration rate (eGFR) erroneously indicates an impaired kidney function.
Michael I. Sponfeldner, Pauline Dürr, Phyllis Lensker, Katja Gessner, Lisa Cuba, Rainer Fietkau, Markus F. Neurath, Bernd Wullich, Marianne Pavel, Carola Berking, Matthias W. Beckmann, Andreas Mackensen, Frank Dörje, Martin F. Fromm   +13 more
wiley   +1 more source

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, EarlyView.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer: Protocol of a Multicenter Cluster-Randomized Trial (MAeSTro-SDM). [PDF]

J Korean Med Sci
Lee EK, Kim MJ, Hwangbo Y, Moon JH, Cho SW, Chai YJ, Choi JY, Jung YS, Lee KE, Chung EJ, Kim K, Kim SJ, Kim W, Kim YH, Lee YK, Jang J, Song YS, Yi KH, Yu HW, Moon S, Jung KY, Kim HJ, Ryu CH, Ryu J, Seok J, Kang SH, Lee S, Chu AJ, Lee CY, Lee JY, Lim H, Kim JH, Park SK, Park YJ.   +33 more
europepmc   +1 more source

Two Pillars of My Path in Cytopathology: Mentorship From Training to Practice

Diagnostic Cytopathology, EarlyView.
ABSTRACT Mentorship has been a cornerstone of my professional development in cytopathology, shaping both my diagnostic acumen and academic identity. Under the guidance of Dr. Claire Michael during residency and fellowship, I was introduced to a culture of intellectual rigor, systems thinking, and continuous improvement.
Hamza N. Gokozan
wiley   +1 more source

Recurrent Orbital Metastases in Follicular Variant Papillary Thyroid Carcinoma After Recombinant Human Thyrotropin. [PDF]

JCEM Case Rep
Ibrahim E, Kurukulasuriya L, Galloway T, Elbanan M, Hashim MMA, Gardner M.   +5 more
europepmc   +1 more source

Preoperative Detection of Dual TERT Promoter Mutations in Thyroid Cancer: A Case Series

Diagnostic Cytopathology, EarlyView.
ABSTRACT Telomerase reverse transcriptase promoter (TERTp) mutations are associated with aggressive thyroid cancer and are most frequently found in anaplastic and poorly differentiated thyroid cancer. Pre‐operative thyroid nodule molecular testing can detect TERTp, denoting a high risk of malignancy and possible aggressive clinical features such as ...
Amir Harari, Jennifer Huiras, Yang Chen, Mohammed Alshalalfa, Yangyang Hao, Joshua P. Klopper, Richard T. Kloos, Bianca J. Vazquez   +7 more
wiley   +1 more source

Cytopathologic Features of Metastatic Malignant Mesothelioma With SMARCB1 (INI‐1) Deficient Diagnosed by Ultrasound‐Guided Fine‐Needle Aspiration: A Case Report

Diagnostic Cytopathology, EarlyView.
ABSTRACT Malignant mesothelioma (MM) is a rare yet aggressive neoplasm that arises from mesothelial cells lining the thoracic and abdominal cavities, the pericardium, and the tunica testis. Characterized by rapid progression, high invasiveness, and a poor prognosis, MM poses significant clinical challenges. SMARCB1, also referred to as INI‐1, hSNF5, or
Jun Yang, Juandi Liu, Jing Jin, Deng Pan, Lei Shao   +4 more
wiley   +1 more source